Inhibikase Therapeutics, Inc.
NASDAQRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) operates as a clinical-stage pharmaceutical company focused on developing protein kinase inhibitor therapeutics, primarily Abelson Tyrosine Kinase inhibitors, to modify the course of cardiopulmonary diseases such as pulmonary arterial hypertension (PAH) and earlier neurodegeneration disorders including Parkinson's disease and related conditions. The company's lead product candidate, IKT-001 (also referred to as IkT-001Pro), comprises a prodrug of imatinib mesylate designed for PAH, an orphan indication affecting approximately 50,000 Americans characterized by pulmonary vascular remodeling and elevated resistance; Risvodetinib (IkT-148009), a selective non-receptor Abelson Tyrosine Kinase (c-Abl) inhibitor targeting Parkinson's disease inside and outside the brain as well as gastrointestinal tract dysfunction and orphan indications like Multiple System Atrophy; and follow-on compounds from its RAMP medicinal chemistry platform for cognitive and motor function diseases. Its multi-therapeutic pipeline additionally encompasses drug delivery technologies for kinase inhibitors, oncology applications such as stable-phase chronic myelogenous leukemia, and potential infectious disease treatments, supported by research collaborations with Johns Hopkins University, Arizona State University, Michigan State University, and Sphaera Pharma Pte. Ltd. Founded in 2008 and headquartered in Atlanta, Georgia, with offices in Wilmington, Delaware, and Lexington, Massachusetts, Inhibikase targets patients with high-unmet-need conditions in the U.S. and pursues global operations through its clinical development programs. Recent developments include a strategic expansion into cardiopulmonary disease following a pre-IND meeting with the U.S. FDA in April 2024 and plans for an IND submission for IKT-001 in PAH during Q3 2024; scaling of IKT-001Pro manufacturing post a pre-NDA FDA meeting in January 2024 to support late-stage trials and NDA requirements; a $100 million public offering of common stock and pre-funded warrants priced on November 20, 2025, expected to close November 24, 2025, providing a cash runway into 2029 primarily to fund an adaptive Phase 3 program for IKT-001 in PAH, broader R&D, potential acquisitions, and corporate purposes; and institutional investments such as Fairmount Funds Management LLC acquiring a 9.90% stake in October 2024 and Sands Capital increasing its holdings to over 13 million shares in November 2025.
Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Inhibikase Therapeutics Announces First Quarter 2026 Financial Results and Highlights Recent Activity
Inhibikase Therapeutics Announces Enrollment of First Patient in IMPROVE-PAH Global Phase 3 Study of IKT-001 in the Treatment of Pulmonary Arterial Hypertension
Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Inhibikase Therapeutics Announces Full Year 2025 Financial Results and Highlights Recent Activity
Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Short Interest Up 52.2% in February
Analyzing Inhibikase Therapeutics (NYSE:IKT) and Big Cypress Acquisition (OTCMKTS:BCYP)
Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Receives Consensus Rating of “Buy” from Analysts
Comparing Inhibikase Therapeutics (NYSE:IKT) and Big Cypress Acquisition (OTCMKTS:BCYP)
Comparing Liminatus Pharma (NASDAQ:LIMN) & Inhibikase Therapeutics (NASDAQ:IKT)
Liminatus Pharma (NASDAQ:LIMN) vs. Inhibikase Therapeutics (NASDAQ:IKT) Head-To-Head Contrast
Liminatus Pharma (NASDAQ:LIMN) and Inhibikase Therapeutics (NASDAQ:IKT) Head-To-Head Survey
Critical Survey: Inhibikase Therapeutics (NASDAQ:IKT) versus Liminatus Pharma (NASDAQ:LIMN)
Analyzing Liminatus Pharma (NASDAQ:LIMN) and Inhibikase Therapeutics (NASDAQ:IKT)
Financial Analysis: Inhibikase Therapeutics (NASDAQ:IKT) and Liminatus Pharma (NASDAQ:LIMN)
Inhibikase Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants
Inhibikase Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Inhibikase Therapeutics Advancing IKT-001 to Global Phase 3 Study in Pulmonary Arterial Hypertension
Inhibikase Therapeutics Announces Third Quarter 2025 Financial Results and Highlights Recent Activity
Inhibikase Therapeutics Strengthens Leadership Team with Appointment of Timothy Pigot as Chief Commercial and Strategy Officer